InflaRx IFRX 深 沪
等待开盘 10-25 09:30:00 美东时间
1.40
+0.180
+14.75%
华盛通- 最 高1.42
- 今 开1.24
- 成交量 108.13万股
- 最 低 1.22
- 昨 收 1.22
- 总市值 9484.59万
- 52周最高 2.815
- 市盈率 静 --
- 换手率 1.60%
- 52周最低 0.7113
- 委 比 -87.29%
- 总股本 6774.71万
- 历史最高 53.10
- 量 比 1.60
- 振 幅 16.39%
- 历史最低 0.7113
- 每 手 1
- 风险率 0.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biogen's Immunology Pipeline Has Long-Term Potential: Analyst
Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases.
今天 00:47
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
InflaRx N.V. announced its participation in Guggenheim Securities' 2nd Annual Healthcare Innovation Conference on November 10-12, 2025, in Boston, MA. The company will host a fireside chat on November 11 at 2:30 PM ET and conduct one-on-one investor meetings on the same day. InflaRx is a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system, with vilobelimab as a key drug candidate.
10-21 11:20
InflaRx regains Nasdaq minimum bid price compliance
InflaRx (NASDAQ:IFRX) on Friday said it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement, per a notice from the exchange dated September 11. Company met the requirement after ...
09-12 20:51
InflaRx Regains Nasdaq Compliance
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced that it has received a written notice (the "Notice"),
09-12 20:36
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
<p>InflaRx N.V. announced that it has regained compliance with Nasdaq's minimum bid price requirement, as its ordinary shares closed at $1.00 or higher for 10 consecutive business days from August 27 to September 10, 2025. The company, which specializes in anti-inflammatory therapeutics targeting the complement system, developed vilobelimab, a novel anti-C5a monoclonal antibody, and is developing INF904, an orally administered C5a receptor inhibi...
09-12 12:30
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.
09-08 17:59
HC Wainwright & Co. Assumes InflaRx at Buy, Announces Price Target of $6
HC Wainwright & Co. analyst Matthew Keller assumes InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $6.
09-02 18:49
InflaRx Announces Participation in September Investor Conferences
InflaRx N.V. will participate in two investor conferences in September 2025: the Cantor Global Healthcare Conference in New York on September 4th and the H.C. Wainwright Global Investment Conference on September 9th. They will present and hold one-on-one meetings. Links to the live streams and replays are available. rtc sean的SDKキー
08-21 11:30
InflaRx shares are trading lower after the company reported worse-than-expected Q2 financial results.
InflaRx shares are trading lower after the company reported worse-than-expected...
08-07 22:46
InflaRx Q2 EPS $(0.24) Misses $(0.17) Estimate, Sales $44.708K Miss $50.167K Estimate
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by 38.73 percent. This is a 7.69 percent increase over losses of $(0.26) per share from the same
08-07 19:36
